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Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare complication of Crohn's disease
(CD), and it is uncertain whether it is associated with CD itself or with its treatment. We describe a case of CIDP-like
neuropathy as an initial symptom of CD. The neurologic symptoms of the patient which responded partially to
intravenous immunoglobulin (IVIG) recovered after resection of the appendiceal CD.
Case presentation: A 17-year-old male had experienced three separate attacks of motor weakness and paresthesia of
all four extremities over a period of 7 months. The electrophysiologic findings revealed a demyelinating sensory-motor
polyneuropathy which was compatible with CIDP. However, repeated intravenous IVIG (2 g/kg) treatment gave only a
partial response. Four days after the last discharge, he was diagnosed as appendiceal CD after surgical resection of a
periappendiceal abscess. His neurologic symptoms and electrophysiologic findings recovered without any maintenance
therapy.
Conclusions: CIDP-like neuropathy can be an initial presentation of CD, and recovery of the CIDP symptoms may
result from resection of the CD. Clinicians should be aware of the possibility of CD in patients with intractable CIDP
symptoms.
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Crohn's disease (CD) is a relapsing, transmural inflam-
matory disease of the gastrointestinal mucosa that can
affect the entire gastrointestinal tract form mouth to
anus [1]. It is considered a systemic disease because
extraintestinal manifestations such as uveitis, arthritis,
pleuritis, myocarditis, primary sclerosing cholangitis,
pancreatitis, ankylosing spondylitis and tendinitis can
develop [1]. Neurologic manifestations can also occur, the
most common being myelopathy, arterial stroke, myop-
athy, multiple sclerosis and epilepsy [2-4]. Peripheral neur-
opathy is also reported to be a neurologic complication,
and it can be associated with immune-mediated inflam-
mation, micronutrient deficiencies (e.g., vitamin B12,* Correspondence: aescula@hanmail.net
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nidazole, TNF-α antagonists) [3,5-8]. A few cases of
chronic inflammatory demyelinating polyneuropathy
(CIDP) have been reported [7-11], but in those cases
the patients developed their symptoms after CD had
been established during various treatments, making it
difficult to determine if they were caused by the dis-
ease or were treatment-related. Here, we describe a
CIDP-like neuropathy patient who had 3 episodes of
motor weakness as the initial presentation of concealed
appendiceal CD. The neurological symptoms and ab-
normal electrophysiologic findings gradually improved
after surgical resection of the appendiceal CD, without
CIDP treatment.Case presentation
A 17-year-old male without any medical history was admit-
ted with ascending weakness of both lower extremities thatis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kim et al. BMC Neurology  (2015) 15:48 Page 2 of 5had progressed for about two weeks. He had upper respira-
tory infection one week ago. At the time of admission, his
upper respiratory infection was improved and physical
examinations in neck, chest and abdomen were unre-
markable. On neurologic examination, he had symmet-
ric weakness of both lower extremities (MRC grade 4)
with paresthesia of both hands and feet. Deep tendon
reflexes were absent in the upper and lower extremities.
Routine laboratory findings, including serum complete
blood count, biochemistry, urine analysis and C-reactive
protein, were normal. Cerebrospinal fluid (CSF) protein
level was elevated at 72 mg/dL without pleocytosis and
immunoglobulin G levels in serum (3370 mg/dL) and
CSF (13.8 mg/dL) were increased. Extensive laboratory
investigations including, thyroid function, anti-nuclear
antibodies, anti-ganglioside, myelin-associated glycopro-
tein and viral markers, were all negative. Motor nerve






CMAP amplitude (mV) 6.1 2.5
Distal latency (m/s) 4.92 11.4
NCV (m/s) 32.2 16.9
F-wave latency (m/s) 40.1 33.4
Ulnar motor, right
CMAP amplitude (mV) 9.4 6
Distal latency (m/s) 3.27 8.4
NCV (m/s) 32.7 21.3
F-wave latency (m/s) 33.6 41.4
Peroneal motor, right
CMAP amplitude (mV) 0.62 No resp
distal latency (m/s) 9.43 No resp
NCV (m/s) 27.3 No resp
F-wave latency (m/s) 80.4 Absent
Tibial motor, right
CMAP amplitude (mV) 3.0 0.56
distal latency (m/s) 5.63 13.6
NCV (m/s) 49.6 46.9
F-wave latency (m/s) 60.2 49.3
Median sensory, right
SNAP amplitude (mV) No response No resp
NCV (m/s) No response No resp
Sural sensory, right
SNAP amplitude (μV) 17.8 No resp
NCV (m/s) 17.9 No resp
Abnormal values are shown in bold.
CMAP: compound muscle action potential, SNAP: sensory nerve action potential, NCcommon peroneal nerves showed prolonged motor ter-
minal latencies and F-wave latencies, and decreased com-
pound muscle action potential (CMAP) amplitudes, sensory
nerve action potential (SNAP) amplitude and nerve conduc-
tion velocity (NCV) (Table 1). Conduction block and tem-
poral dispersion were also seen in the NCS, compatible
with demyelinating polyneuropathy (Figure 1A). With the
impression of AIDP, we started intravenous immuno-
globulin (0.4 g/kg per day) for 5 days and the patient was
discharged after subjective improvement of neurological
symptoms.
Eight weeks after the first onset of symptoms, he com-
plained of further progressive motor weakness and tingling
sensations in the four extremities. Electrophysiologic stud-
ies showed that the demyelinating sensory-motor polyneur-
opathy had worsened since the previous study (Table 1,
Figure 1B). Guillain-Barré syndrome with treatment-related
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V: nerve conduction velocity.
Figure 1 Serial changes of compound motor action potentials (CMAPs) of the median and tibial nerves. (A) The first attack before the
first intravenous immunoglobulin, (B) the second attack 8 weeks after the first attack, (C) the third attack 4 months after the second treatment,
and (D) 6 months after appendectomy without immuno-modulating therapy.
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administered for 5 days, again with clinical improve-
ment of symptoms.
Four months after the second event, the patient com-
plained of recurrent progressive motor weakness and sen-
sory changes. Repeated NCS showed no evoked responses
in the median, ulnar, tibial and common peroneal nerves,
which was compatible with severe demyelination (Table 1,
Figure 1C). With the impression of CIDP, immunoglobu-
lin (0.4 g/kg per day) was administered for 5 days and
there was only slight improvement of symptoms.
Four days after the last discharge, the patient visited
the emergency department on account of newly devel-
oped severe pain in the right lower abdominal quadrant
with fever. He had no gastrointestinal symptoms, includ-
ing diarrhea, prior to development of the abdominal pain.
Physical examination of the abdomen revealed tenderness
and rebound tenderness on the right lower quadrant.
Abdominal computed tomography (CT) prompted suspi-
cion of a periappendiceal abscess, and emergent surgical
resection of the ileum, cecum and appendix was per-
formed. Appendiceal biopsy revealed diffuse wall thicken-
ing due to transmural lymphocytic infiltration and fibrosis,Figure 2 Pathologic findings of Crohn’s disease involving the append
lymphocytic infiltration and fibrosis, with scattered granulomas (A, arrows,
granuloma is present in the mucosa (B, H&E, original magnification x200).with scattered non-necrotizing granulomas, which was
compatible with Crohn’s disease (Figure 2). Since it
was localized to the appendix and subsequent gastrofi-
berscopy and colonofiberscopy were unremarkable, he
was diagnosed with appendiceal Crohn's disease. After
resection of the appendiceal Crohn's disease his motor
weakness and the sensory change in all four limbs grad-
ually recovered without any maintenance treatment. Motor
nerve conduction study after seven months showed im-
provement of electrophysiologic parameters and waveforms
(Table 1, Figure 1D). After 12 months of appendectomy, he
only showed minimal motor and sensory deficits on ex-
tremities and he was able to run. Also there are no gastro-
intestinal symptoms including diarrhea after surgery until
that time.Conclusions
We report the first case in which CIDP-like neuropathy
was the initial presentation of concealed CD. We may
assume that the CIDP-like neuropathy was the initial
symptom of CD since recurrent and intractable neuro-
logical symptoms preceded the diagnosis of CD, and theix. The appendiceal wall is diffusely thickened by transmural
H&E, original magnification x40). A large, well-formed, non-necrotizing
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surgical resection of the appendiceal CD.
The origin of CIDP is still unclear, but it is widely
accepted that it is an autoimmune disease with under-
lying immunopathology involving autoreactive T cells
and B cells [12]. Because CIDP has an autoimmune
basis, it can occur in association with diseases such as
HIV infection and hepatitis C, Sjogren's syndrome, mono-
clonal gammopathy of unknown significance, melanoma,
lymphoma, diabetes and inflammatory bowel diseases
[12]. Only 8 cases of CIDP associated with CD have
been reported and we summarized in the Table 2 when
clinical information were available [7-11,13]. Of those,
5 cases had already been diagnosed as CD 1 to 30 years
before CIDP symptoms developed [7-9]. Since nutritional
deficiency or treatment-related neurotoxicity could have
occurred during those periods, it is unclear whether
the CIDP was caused by the CD itself or by other
mechanisms.
In the two other cases the CIDP and CD occurred at
the same time, but the patients had only one acute pro-
gressive symptom, which was not differentiated from
acute inflammatory demyelinating polyradiculoneuropathy
(AIDP) [10,11]. In addition, they had abdominal symptoms
including diarrhea and rectal hemorrhage. Our patient suf-
fered recurrent motor weakness and sensory changes on
three occasions over a 7 month period. He also had ele-
vated CSF protein and typical demyelinating-type nerve-
conduction findings. Although we did not perform a nerve
biopsy and did not confirmed same T-cells from appendix,
CSF and nerve, we were able to diagnose the patient as
CIDP. The most important and unique finding in this case
was that his sensory and motor symptoms developed grad-
ually over 7 months, in very close temporal association to
the onset of IBD symptoms. Considering that Crohn’s
disease is not an acute disease with sudden onset,
extra-intestinal immunologic effects due to the disease
itself may have led to recurrent CIDP like symptoms.Table 2 Cases of CIDP associated with Crohn's disease
Reference Age/Sex IBD activity Gap IBD trea
our case 18/M CA −7 months none
6 60/F RR 30 years TNF-α a
7 49/M Q 20 years none
7 47/F RR 1 years etanerce
7 50/M RR 23 years azathiop
8 36/M CA 4 years mesalaz
azathiop
9 32/M CA 0 year none (n
10 63/F CA 0 year none (n
CA, currently active; Q, quiescent; RR, remitting/relapsing; UK, unkown; IVIg, intravenConsidering that Crohn's disease is not an acute disease
with sudden onset, subclinical immunologic effects due to
the disease itself may lead to recurrent CIDP symptoms.
Therefore, we would cautiously suggest that we should
consider inflammatory bowel disease as a hidden possible
concurrent or preceding disease when a patient has recur-
rent episodes of CIDP.
Another noteworthy finding in our patient is that he
recovered from the CIDP symptoms after resection of
the appendiceal CD. Although 3 times of IVIG treatment
could have influenced the clinical course of the patient,
there was only minimal responses before removal of the
periappendiceal abscess. Furthermore, the symptoms and
electrophysiological findings gradually improved without
any treatment for CIDP. Based on our patient’s clinical
courses, we believe that surgical resection may have more
pronounce effect on clinical stabilization of the patient.
CD confined to the appendix occurs in younger patients
and is known to be less aggressive and have a low recur-
rence rate [14,15]. It can also be the primary or sole mani-
festation of the disease. Since, appendiceal biopsy of our
patient revealed non-caseous granulomas, and colonofi-
berscopy showed no granulomatous lesions, he was di-
agnosed as appendiceal CD. Considering our patient’s
clinical course, it is possible that the appendiceal CD
may have influenced the CIDP-like neuropathy. Appendix
is known as an immunological organ, and it may have vari-
able effects on immunologic diseases such as idiopathic in-
flammatory bowel disease and CIDP-like neuropathy. In
this case, CIDP-like neuropathy symptoms were stabilized
after surgical resection of the appendiceal CD. We suggest
that common immunologic mechanism could be present
in those two diseases and non-aggressive limited disease
may develop distant neurological symptoms by immuno-
logic mechanisms.
In summary, we describe a case of CIDP as an initial
presentation of CD, with recovery of the CIDP symp-
toms after resection of the appendiceal CD. We suggesttment CIDP treatment
IVIG
ntagonist (infliximab) IVIG, prednisolone, azathioprine
IVIG, plasmapheresis, fludarabine,
methotrexate





ewly diagnosed) IVIG, prednisolone, azathioprine
ewly diagnosed) IVIG, prednisolone
ous immunoglobulin.
Kim et al. BMC Neurology  (2015) 15:48 Page 5 of 5that inflammatory bowel disease should be considered a
possible underlying disease when investigating patients
with CIDP.
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